渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

休市中 07-24 16:00:00 EDT

202.19

+1.57

+0.78%

盘后201.80

-0.39-0.19%

19:40 EDT

最高203.30	最低200.04	成交量59.64万
今开202.24	昨收200.62	日振幅1.63%
总市值298.51亿	流通市值297.86亿	总股本1.48亿
成交额1.21亿	换手率0.40%	流通股本1.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":202.19,"timestamp":1784923200000,"preClose":200.62,"halted":0,"volume":596372,"hourTrading":{"tag":"盘后","latestPrice":201.8,"preClose":202.19,"latestTime":"19:40 EDT","volume":31634,"amount":6395293.1824,"timestamp":1784936446612,"change":-0.39,"changeRate":-0.001929,"amplitude":0.00455},"delay":0,"changeRate":0.007825740205363339,"floatShares":147314660,"shares":147637117,"eps":9.296136,"marketStatus":"休市中","change":1.57,"latestTime":"07-24 16:00:00 EDT","open":202.24,"high":203.3,"low":200.035,"amount":120618360.08432,"amplitude":0.016275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":9.296136,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":200.62,"preHourTrading":{"tag":"盘前","latestPrice":200.62,"preClose":200.62,"latestTime":"09:06 EDT","volume":17,"amount":3410.43001,"timestamp":1784898370312,"change":0,"changeRate":0,"amplitude":0.00005},"postHourTrading":{"tag":"盘后","latestPrice":201.8,"preClose":202.19,"latestTime":"19:40 EDT","volume":31634,"amount":6395293.1824,"timestamp":1784936446612,"change":-0.39,"changeRate":-0.001929,"amplitude":0.00455},"volumeRatio":0.6425547210087452,"impliedVol":0.4071,"impliedVolPercentile":0.7928},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"1198085382","title":"财报前瞻｜渤健公司本季度营收预计增5.93%，机构观点看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1198085382","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198085382?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:54","pubTimestamp":1784685267,"startTime":"0","endTime":"0","summary":"渤健公司将于2026年07月29日盘前发布最新季度财报，市场关注Leqembi商业化进展与利润率变化对单季表现的影响。市场一致预期本季度营收24.61亿美元，同比增长5.93%；调整后每股收益3.09美元，同比下降20.05%；息税前利润6.07亿美元，同比下降14.80%。上季营收24.78亿美元，同比增长1.93%；毛利率75.37%；归属于母公司股东的净利润3.19亿美元，同比增长32.85%；净利率12.89%；调整后每股收益3.57美元，同比增长18.21%。从近期可获取的机构观点看，看多意见占优。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜渤健公司本季度营收预计增5.93%，机构观点看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170294160","title":"异动解读｜渤健公司盘中上涨5.03%，加拿大药品管理机构建议将Leqembi纳入公共医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1170294160","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170294160?lang=zh_cn&edition=full","pubTime":"2026-07-17 01:15","pubTimestamp":1784222152,"startTime":"0","endTime":"0","summary":"7月17日，渤健公司盘中上涨5.03%，报207.24美元/股，成交额1.62亿美元。消息面上，加拿大药品管理机构正式认可Leqembi的临床价值，建议将其纳入公共医保覆盖范围用于治疗早期阿尔茨海默病。Leqembi由渤健与卫材共同开发，一季度收入已同比大增74%至1.68亿美元。此前一个交易日渤健曾因Diranersen二期未达主要终点而下跌逾7%，本次反弹显示市场对Leqembi商业化前景的信心有所修复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169524809","title":"卫材：加拿大药品管理机构认可Leqembi临床价值，建议将早期阿尔茨海默病纳入公共医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1169524809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169524809?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:17","pubTimestamp":1784204253,"startTime":"0","endTime":"0","summary":"加拿大药品管理机构已正式认可Leqembi的临床价值，并建议将其纳入公共医保覆盖范围，用于治疗早期阿尔茨海默病。这一积极建议标志着该创新疗法在获得更广泛患者可及性的道路上迈出了关键一步。Leqembi由卫材与渤健公司共同开发，是一种针对阿尔茨海默病潜在病理机制的靶向疗法。加拿大相关机构的认可，是基于其临床试验所展现出的减缓疾病进展的明确证据。此举若最终获得采纳，将显著减轻早期阿尔茨海默病患者及其家庭的经济负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BIIB","IE00B19Z9Z06.USD","BK4533","LU0889565916.HKD","LU0234570918.USD","IE00B19Z9P08.USD","BK4139","LU0109394709.USD","PBE","IE00B894F039.SGD","BK4532","BMED","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651946677","title":"a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651946677","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651946677?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:35","pubTimestamp":1784122530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由 A16z 支持的临床阶段生物制药公司 Braveheart Bio Inc. 于周三向纳斯达克提交了 IPO 申请。这家心血管疾病药物开发商将寻求通过在纳斯达克全球市场销售股份来募集一笔尚未公布具体金额的资金。百健首席执行官克里斯托弗·维巴赫担任 Braveheart 的董事长。Braveheart 报告称，在 2026 年前三个月，其净亏损为 1430 万美元，并创造了约 1100 万美元的收入。相比之下，去年同期的前三个月净亏损为 9.9 万美元。Braveheart 将以股票代码“BRVE”进行交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4588","BMED","LU0109394709.USD","PBE","BK4533","IE00B894F039.SGD","LU0320765992.SGD","LU0889565916.HKD","BIIB","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0234570918.USD","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199762348","title":"Leqembi®真实世界领先研究在AAIC® 2026发布：超75%早期阿尔茨海默病患者在平均17个月治疗期内保持稳定，近7%出现改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1199762348","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199762348?lang=zh_cn&edition=full","pubTime":"2026-07-14 23:16","pubTimestamp":1784042182,"startTime":"0","endTime":"0","summary":"Leqembi®真实世界领先研究在AAIC® 2026年会上公布的数据显示，在该研究中，超过75%的早期阿尔茨海默病患者在接受平均17个月的治疗后病情保持稳定，同时有近7%的患者病情出现改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0109394709.USD","IE00B894F039.SGD","BMED","LU0320765992.SGD","BIIB","BK4532","LU0234570918.USD","BK4585","IE00B19Z9Z06.USD","PBE","BK4139","IE00B19Z9P08.USD","BK4533","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125542301","title":"异动解读｜渤健公司盘中下跌7.06%，Diranersen二期CELIA完整数据公布后股价急挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1125542301","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125542301?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:24","pubTimestamp":1784039055,"startTime":"0","endTime":"0","summary":"消息面上，公司在阿尔茨海默病协会国际会议上公布了Diranersen的二期CELIA研究完整数据，并宣布将推进该药至三期临床。尽管数据显示Diranersen在Tau蛋白降低和认知获益方面表现积极，但该研究此前已确认未达到主要终点——CDR-SB评分的剂量反应评估未获满足，市场对其注册开发路径仍存疑虑。摩根士丹利此前按30%成功概率估算Diranersen约贡献公司2035年总收入的10%，市场对该药物的风险定价仍在消化调整中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132952984","title":"渤健公司于AAIC公布Celia二期数据：Diranersen在早期阿尔茨海默病中展现显著临床获益与强劲Tau蛋白降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1132952984","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132952984?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:16","pubTimestamp":1784034993,"startTime":"0","endTime":"0","summary":"渤健公司近日在阿尔茨海默病协会国际会议上公布了其候选药物Diranersen的Celia二期研究数据。结果显示，该药物在治疗早期阿尔茨海默病患者时，不仅带来了具有临床意义的积极结局，更实现了Tau蛋白水平的强劲降低。这一积极信号为针对这一复杂神经退行性疾病的靶向治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4533","BK4139","IE00B19Z9P08.USD","BIIB","LU0320765992.SGD","IE00B19Z9Z06.USD","LU0234570918.USD","IE00B894F039.SGD","PBE","LU0109394709.USD","BK4588","BMED","BK4585","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651106049","title":"百健(BIIB.US)：将推进阿尔茨海默病药物Diranersen至3期临床。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651106049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651106049?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:15","pubTimestamp":1784034918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4585","BK4139","BK4532","LU0234570918.USD","IE00B19Z9P08.USD","LU0109394709.USD","BK4533","BK4588","BIIB","IE00B894F039.SGD","PBE","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651754101","title":"FDA批准勃健(BIIB)阿尔茨海默病新药皮下剂型 拓展居家治疗应用场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2651754101","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651754101?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:31","pubTimestamp":1784017876,"startTime":"0","endTime":"0","summary":"本次剂型获批基于严谨的临床对比数据，临床试验证实，Leqembi皮下注射剂型的治疗效果、药效稳定性与原有静脉注射剂型高度一致，疗效水平无显著差异。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302523","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0234570918.USD","IBRN","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BIIB","IE00B894F039.SGD","LU0889565916.HKD","BK4533","BK4585","ESALF","BK4532","ESAIY","MNTL","BK4588","LABU","BMED","PBE","BK4139","BK4007","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191345039","title":"FDA批准Leqembi Iqlik®（lecanemab-irmb）皮下注射剂作为早期阿尔茨海默病的起始剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1191345039","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191345039?lang=zh_cn&edition=full","pubTime":"2026-07-14 05:37","pubTimestamp":1783978636,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Leqembi Iqlik®（lecanemab-irmb）皮下注射剂，作为治疗早期阿尔茨海默病的起始剂量方案。这一决定为患者提供了一种新的、便捷的给药选择，有望改善治疗的可及性与依从性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0109394709.USD","BK4139","PBE","BK4585","LU0234570918.USD","IE00B19Z9Z06.USD","BIIB","BK4588","BK4533","BMED","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175822678","title":"异动解读｜渤健公司盘中上涨5.26%，FDA批准Leqembi皮下注射新起始给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1175822678","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175822678?lang=zh_cn&edition=full","pubTime":"2026-07-14 03:44","pubTimestamp":1783971880,"startTime":"0","endTime":"0","summary":"消息面上，FDA正式批准Leqembi皮下注射剂型用于治疗阿尔茨海默病的新起始给药方案。此前一日，渤健与卫材在阿尔茨海默病协会国际会议上公布数据显示，每周一次500mg皮下注射Leqembi在药物暴露量上与已获批的静脉输注起始方案生物等效，支持相当的淀粉样蛋白清除效果、临床疗效及安全性。皮下注射剂型获批为患者提供了更便捷的居家替代方案，有望进一步推动Leqembi销售增长——该药一季度收入已同比大增74%至1.68亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120715125","title":"FDA批准Leqembi皮下注射剂型治疗阿尔茨海默病的新起始给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1120715125","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120715125?lang=zh_cn&edition=full","pubTime":"2026-07-14 02:08","pubTimestamp":1783966119,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Leqembi皮下注射剂型用于治疗阿尔茨海默病的新起始给药方案。这一监管决定为患者提供了更便捷的治疗选择，有望改善用药依从性。\nLeqembi由渤健公司（Biogen）与合作伙伴共同开发，此次新方案的获批标志着其在阿尔茨海默病治疗领域取得了又一重要进展。皮下注射剂型相较于静脉输注，能简化给药流程，为患者和护理人员带来便利。\n新起始剂量方案的确定基于临床数据，旨在优化治疗效果并管理潜在风险。随着全球阿尔茨海默病患者数量持续增长，此类创新疗法的推进对满足未竟医疗需求具有重要意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","BK4533","LU0109394709.USD","BK4139","BMED","IE00B19Z9Z06.USD","BK4532","LU0889565916.HKD","LU0234570918.USD","LU0320765992.SGD","BK4585","IE00B19Z9P08.USD","BK4588","BIIB","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127250118","title":"异动解读｜渤健公司盘中上涨5.86%，宣布暂停大部分Apellis研究项目聚焦核心管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1127250118","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127250118?lang=zh_cn&edition=full","pubTime":"2026-06-26 23:01","pubTimestamp":1782486100,"startTime":"0","endTime":"0","summary":"6月26日，渤健公司盘中上涨5.86%，报213.79美元/股，成交额1.01亿美元。消息面上，渤健公司当日宣布已决定暂停或终止对绝大部分传统Apellis研究项目的投资，并对原属Apellis的临床及临床前产品组合进行全面审查，以评估其与公司战略的契合度。市场将此举解读为公司主动优化研发投入、聚焦更具潜力的核心管线，有助于改善资源配置效率。此前渤健已于今年完成对Apellis的收购及以最高10亿美元收购RayThera，持续扩展免疫学布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133029467","title":"渤健公司发言人：对前Apellis临床及临床前产品组合进行全面审查，以进一步评估战略契合度","url":"https://stock-news.laohu8.com/highlight/detail?id=1133029467","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133029467?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:55","pubTimestamp":1782474923,"startTime":"0","endTime":"0","summary":"渤健公司发言人表示，公司目前正在对原属Apellis的临床及临床前产品组合进行全面审查。此举旨在深入评估这些资产与公司自身发展战略的契合程度，从而为未来的战略决策提供依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4588","IE00B19Z9P08.USD","LU0889565916.HKD","BK4533","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","BK4139","IE00B894F039.SGD","LU0320765992.SGD","BK4585","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148709868","title":"渤健公司决定暂停或终止对大部分传统Apellis研究项目的投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1148709868","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148709868?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:55","pubTimestamp":1782474912,"startTime":"0","endTime":"0","summary":"渤健公司发言人表示，公司已决定暂停或终止对绝大部分传统Apellis研究项目的投资。这一举措标志着渤健在研发战略上的一次重大调整，旨在重新配置资源，聚焦于更具潜力的核心管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BIIB","IE00B894F039.SGD","BK4533","IE00B19Z9Z06.USD","BK4532","BK4585","LU0109394709.USD","IE00B19Z9P08.USD","BK4139","LU0889565916.HKD","LU0234570918.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644082762","title":"渤健(BIIB)最高10亿美元收购RayThera 持续加码自身免疫学管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2644082762","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644082762?lang=zh_cn&edition=full","pubTime":"2026-06-18 23:17","pubTimestamp":1781795862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物制药巨头渤健  达成收购私营生物科技企业 RayThera 的交易，整体交易对价上限 10 亿美元，交易结构由前期预付款与多阶段临床、监管里程碑分成款项构成，交易完成后将全面补强渤健自身免疫疾病产品矩阵。消息公布周四盘前，渤健股价小幅上涨 0.5%，前一交易日收盘涨幅 1.6%。RayThera 核心管线储备多款抗炎候选药物，适配各类免疫介导类疾病治疗，企业核心候选分子预计今年三季度初启动一期临床开发。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0320765992.SGD","BK4588","IE00B894F039.SGD","LU0889565916.HKD","LU0234570918.USD","BIIB","BK4532","BK4139","IE00B19Z9Z06.USD","BK4585","BK4533","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135997390","title":"盘前异动｜绩优股拉升，TTAN、AGX大涨，芯片、光通信概念普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1135997390","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135997390?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:21","pubTimestamp":1780647663,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前交易时段涨跌不一。","market":"us","thumbnail":"https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","TTAN","LULG","LITE","LULU","AGX","ZUMZ","LITX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640593626","title":"优时比与百健(BIIB.US)狼疮新药dapirolizumab pegol三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2640593626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640593626?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:56","pubTimestamp":1780297012,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，优时比和百健周一宣布，双方联合开发的在研药物dapirolizumab pegol在治疗系统性红斑狼疮的三期临床试验中达到了主要终点。试验数据显示，用药组患者在第 48 周实现 BICLA 应答的比例达 50%，安慰剂组为 35%，组间差异具有统计学意义。BICLA 是一项复合疗效终点指标，用于评估患者所有受累器官系统的疾病活动度是否出现具有临床意义的改善，同时其他狼疮相关病症未发生恶化。安全性方面，该药严重不良事件发生率为 10%，低于安慰剂组的 14.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00B19Z9P08.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4139","BK4532","BK4585","BK4533","BK4588","IE00B894F039.SGD","LU0109394709.USD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638850232","title":"百健(BIIB.US)MS业务承压：意大利子公司遭反垄断突击检查，被指控滥用检测捆绑销售阻止竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2638850232","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638850232?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:23","pubTimestamp":1779880991,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，意大利竞争与市场管理局正式宣布对Biogen Italia及其美国母公司百健启动反垄断调查，指控其涉嫌滥用市场支配地位，通过捆绑一种用于患者安全筛查的医学检测，系统性阻止竞争对手Sandoz的廉价生物类似药进入意大利多发性硬化症治疗市场。百健随后通过电子邮件声明回应称，公司正在\"全力配合当局调查\"，并确认AGCM代表已于周二上午到访其米兰办事处。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"百健(BIIB.US)MS业务承压：意大利子公司遭反垄断突击检查，被指控滥用检测捆绑销售阻止竞争","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765646.SGD","LU1720051017.SGD","LU2023251221.USD","IE00BZ1G4Q59.USD","LU2028103732.USD","LU0267386448.USD","LU1989772840.SGD","LU2487616109.SGD","LU1074936037.SGD","BK4533","LU1363072403.SGD","LU1791710582.SGD","LU2133065610.SGD","BK4504","LU1791710400.SGD","LU0106261372.USD","LU1162221912.USD","BIIB","BK4139","BK4588","LU0314104364.USD","LU0098860793.USD","LU1988902786.USD","LU1720051108.HKD","BK4585","IE00B19Z9Z06.USD","LU1732800096.USD","LU2347655156.SGD","LU1244550494.USD","IE00B894F039.SGD","LU0528227936.USD","LU0795875169.SGD","LU2357305700.SGD","LU2271345857.HKD","IE00B19Z9P08.USD","LU1064131342.USD","LU0882574139.USD","LU0225283273.USD","LU2264538146.SGD","BK4127","LU0390134368.USD","LU1668664300.SGD","LU0106831901.USD","LU1548497426.USD","LU0971096721.USD","LU0210528500.USD","LU1244550221.USD","LU2111349929.HKD","LU0557290698.USD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179602120","title":"渤健与Denali Therapeutics公布早期帕金森病药物Biib122（Dnl151）IIb期Luma研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1179602120","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179602120?lang=zh_cn&edition=full","pubTime":"2026-05-22 06:00","pubTimestamp":1779400816,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）与Denali Therapeutics Inc. 近日就双方共同研发的、针对早期帕金森病的在研药物Biib122（亦称Dnl151）的IIb期临床试验（Luma研究）提供了最新进展信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","LU0320765992.SGD","DNLI","LU0234570918.USD","BK4585","LU0109394709.USD","BK4533","BK4532","BK4535","BIIB","BK4548","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com;investors.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.013},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1783},{"period":"1year","weight":0.5249},{"period":"ytd","weight":0.1489}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性生物制药公司，致力于为患有严重复杂疾病的人发现、开发和提供创新疗法。该公司拥有广泛的多发性硬化症（MS）药物组合，推出了首个获批治疗脊髓性肌萎缩症（SMA）的药物，共同开发了解决阿尔茨海默病定义病理学的治疗方法，并推出了首个获批的针对肌萎缩侧索硬化症（ALS）遗传原因的疗法。渤健还销售第一个也是唯一一个批准用于治疗16岁及以上成人和青少年的弗里德赖希共济失调（FA）的药物。其研发工作专注于神经病学、专业免疫学和罕见病，并得到内部项目、合作和收购的支持。该公司将生物制剂和生物仿制药商业化，并与领先的制药公司保持战略合作伙伴关系，以推进其产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.039226},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.00281},{"month":3,"riseRate":0.485714,"avgChangeRate":-0.023881},{"month":4,"riseRate":0.342857,"avgChangeRate":-0.019659},{"month":5,"riseRate":0.628571,"avgChangeRate":0.03345},{"month":6,"riseRate":0.485714,"avgChangeRate":0.019046},{"month":7,"riseRate":0.657143,"avgChangeRate":0.031889},{"month":8,"riseRate":0.588235,"avgChangeRate":0.030673},{"month":9,"riseRate":0.5,"avgChangeRate":0.023197},{"month":10,"riseRate":0.542857,"avgChangeRate":0.058896},{"month":11,"riseRate":0.6,"avgChangeRate":0.018187},{"month":12,"riseRate":0.457143,"avgChangeRate":0.034185}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}